PRA Health Sciences Announces Appointment of New Director
14 October 2015 - 7:15AM
PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the
appointment of Linda S. Grais, M.D. to the Board of Directors of
the Company. As a member of the Board of Directors, Dr. Grais will
also serve on the Audit Committee.
“We are delighted that Linda will be joining our
Board of Directors. With her extensive experience in the healthcare
field as a physician, attorney, and biotechnology entrepreneur, Dr.
Grais will bring a valuable perspective to our Board,” said Colin
Shannon, President, Chief Executive Officer and Chairman of the
Board of Directors of PRA Health Sciences, Inc.
Dr. Grais has served as a member of the board of
directors of Ocera Therapeutics, Inc. since January 2008 and as
president and chief executive officer of Ocera Therapeutics, Inc.
since June 2012. Prior to her employment by Ocera, Dr. Grais served
as a managing member at InterWest Partners, a venture capital firm
from May 2005 until February 2011. From July 1998 to July 2003, Dr.
Grais was a founder and executive vice president of SGX
Pharmaceuticals Inc., a drug discovery company focusing on new
treatments for cancer. Prior to that, she was a corporate attorney
at Wilson Sonsini Goodrich & Rosati, where she practiced in
such areas as venture financings, public offerings and strategic
partnerships. Before practicing law, Dr. Grais worked as an
assistant clinical professor of Internal Medicine and Critical Care
at the University of California, San Francisco. Dr. Grais received
a B.A. from Yale University, an M.D. from Yale Medical School and a
J.D. from Stanford Law School. She currently serves on the board of
directors of Arca Biopharma, Inc. and sits on its compensation and
nominating and governance committees.
ABOUT PRA HEALTH SCIENCESAt PRA
Health Sciences, providing innovative solutions for our clients is
what we do. Side-by-side with our clients, we strive to move drug
discovery forward, helping them to develop life-saving and
life-improving drugs. PRA has more than 11,000 employees working in
80+ countries providing comprehensive clinical development services
across all phases. From full service clinical development to the
pioneering Embedded Solutions™ model, PRA provides a broad spectrum
of solutions that meet the demands of a diverse marketplace. PRA
has worked on 100+ marketed drugs across several therapeutic areas
and conducted the pivotal or supportive trials that led to FDA
and/or international regulatory approval of 50+ such drugs.
Investor Inquiries: InvestorRelations@prahs.com
Media Inquiries: Christine Rogers, rogerschristine@prahs.com, +1 919.786.8463
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Sep 2024 to Oct 2024
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about PRA Health Sciences Inc (NASDAQ): 0 recent articles
More News Articles